Use of Topical Finasteride in Hirsutism: A Double-blind, Randomized Clinical Trial on Women

Document Type : Original Article(s)

Authors

1 Professor, Skin Diseases and Leishmaniasis Research Center And Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Resident, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran And Department of Dermatology, School of Medicine And Student Research committee, Isfahan University of Medical Sciences, Isfahan, Iran

3 Professor, Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Finasteride partially blocks the conversion of testosterone to dihydrotestosterone through inhibition of 5α-reductase in hair follicles. Finasteride cream can penetrate into the dermis and the hair follicle due to its solubility. Therefore, it is expected to be used in the treatment of hirsutism with fewer systemic adverse side effects. This study was designed to determine the efficacy of finasteride cream 0.5% in the management of idiopathic hirsutism.Methods: Finasteride (0.5%) and placebo creams were administered to 35 women with facial hirsutism. Medication and placebo creams were each used on one side of the face in an area of excessive hair growth, which were not necessarily symmetrical. The side of the face for the finasteride and placebo creams was chosen randomly and blindly in 1cm2 areas on each side of the face. The hairs were counted and their thickness was also measured by micrometer, and their mean was calculated at the start of therapy and after 6 months. Statistical analysis was done in SPSS software using Paired and Student t-tests. P-values less than 0.05 were considered significant.Findings: The mean of hair numbers decreased on the placebo-applied side from 12.20 ± 6.15 to 10.50 ± 4.90 (P < 0.001), and on the finasteride-treated side from 11.37 ± 6.15 to 8.47 ± 4.62 (P < 0.001). Mean of hair thickness on the placebo side decreased from 2.92 ± 0.84 µm to 2.72 ± 0.79 µm (P < 0.001), and on the finasteride side from 3.17 ± 0.90 µm to 2.37 ± 0.79 µm (P < 0.001). Comparison of hair number and thickness showed no statistically significant changes in finasteride versus placebo treated sides. However, according to the patients' view points, hair growth rate was diminished and hair was thinner on the finasteride-treated side. Conclusion: Six months of topically applied finasteride (0.5%) does not affect the number and thickness of facial hirsutism significantly. Despite the lack of changes, on questioning, most patients in the finastride group perceived a decrease in hair growth over time.

Keywords

References

  1. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327(17): 1185-91.
  2. Stoner E. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol 1992; 147(5): 1298-302.
  3. Djavan B, Zlotta A, Schulman C, Teillac P, Iversen P, Boccon GL, et al. Chemotherapeutic prevention studies of prostate cancer. J Urol 2004; 171(2 Pt 2): S10-3.
  4. Diani AR, Mulholland MJ, Shull KL, Kubicek MF, Johnson GA, Schostarez HJ, et al. Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab 1992; 74(2): 345-50.
  5. Uno H, Kurata S. Chemical agents and peptides affect hair growth. J Invest Dermatol 1993; 101(1 Suppl): 143S-7S.
  6. Camacho FM, Randall VA, Price VH. Hair and its disorders: biology, pathology and management. London: Dunitz; 2000.
  7. Mellin TN, Busch RD, Rasmusson GH. Azasteroids as inhibitors of testosterone 5 alpha-reductase in mammalian skin. J Steroid Biochem Mol Biol 1993: 44(2): 121-31.
  8. Serafini P, Lobo RA. Increased 5 alpha-reductase activity in idiopathic hirsutism. Fertil Steril 1985; 43(1): 74-8.
  9. Rittmaster RS. Treating hirsutism. Endocrinologist 1993; 3(3): 211-8.
  10. Rittmaster RS. Finasteride. N Engl J Med 1994; 330(2): 120-5.
  11. Sahin Y, Dilber S, Kelestimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 2001; 75(3): 496-500.
  12. Johnson L, George FW, Neaves WB, Rosenthal IM, Christensen RA, Decristoforo A, et al. Characterization of the testicular abnormality in 5 alpha-reductase deficiency. J Clin Endocrinol Metab 1986; 63(5): 1091-9.
  13. Imperato-McGinley J, Miller M, Wilson JD, Peterson RE, Shackleton C, Gajdusek DC. A cluster of male pseudohermaphrodites with 5 alpha-reductase deficiency in Papua New Guinea. Clin Endocrinol (Oxf) 1991; 34(4): 293-8.
  14. Serafini P, Ablan F, Lobo RA. 5 alpha-Reductase activity in the genital skin of hirsute women. J Clin Endocrinol Metab 1985; 60(2): 349-55.
  15. Fruzzetti F, de LD, Parrini D, Ricci C. Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J Clin Endocrinol Metab 1994; 79(3): 831-5.
  16. Moghetti P, Castello R, Magnani CM, Tosi F, Negri C, Armanini D, et al. Clinical and hormonal effects of the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism. J Clin Endocrinol Metab 1994; 79(4): 1115-21.
  17. Castello R, Tosi F, Perrone F, Negri C, Muggeo M, Moghetti P. Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up. Fertil Steril 1996; 66(5): 734-40.
  18. Tolino A, Petrone A, Sarnacchiaro F, Cirillo D, Ronsini S, Lombardi G, et al. Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil Steril 1996; 66(1): 61-5.
  19. Faloia E, Filipponi S, Mancini V, Di MS, Mantero F. Effect of finasteride in idiopathic hirsutism. J Endocrinol Invest 1998; 21(10): 694-8.
  20. Bayhan G, Bahceci M, Demirkol T, Ertem M, Yalinkaya A, Erden AC. A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism. Clin Exp Obstet Gynecol 2000; 27(3-4): 203-6.
  21. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000; 85(1): 89-94.
  22. Wong IL, Morris RS, Chang L, Spahn MA, Stanczyk FZ, Lobo RA. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995; 80(1): 233-8.
  23. Erenus M, Yucelten D, Durmusoglu F, Gurbuz O. Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism. Fertil Steril 1997; 68(6): 1000-3.
  24. Lucas KJ. Finasteride cream in hirsutism. Endocr Pract 2001; 7(1): 5-10.
  25. Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 1996; 30(1): 16-27.
  26. Price TM, Allen S, Pegram GV. Lack of effect of topical finasteride suggests an endocrine role for dihydrotestosterone. Fertil Steril 2000; 74(2): 414-5.
  27. Rittmaster RS, Loriaux DL. Hirsutism. Ann Intern Med 1987; 106(1): 95-107.
  28. Couzinet B, Pholsena M, Young J, Schaison G. The impact of a pure anti-androgen (flutamide) on LH, FSH, androgens and clinical status in idiopathic hirsutism. Clin Endocrinol (Oxf) 1993; 39(2): 157-62.
  29. Cusan L, Dupont A, Belanger A, Tremblay RR, Manhes G, Labrie F. Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol 1990; 23(3 Pt 1): 462-9.
  30. Akalin S. Effects of ketoconazole in hirsute women. Acta Endocrinol (Copenh) 1991; 124(1): 19-22.
  31. Venturoli S, Fabbri R, Dal PL, Mantovani B, Capelli M, Magrini O, et al. Ketoconazole therapy for women with acne and/or hirsutism. J Clin Endocrinol Metab 1990; 71(2): 335-9.
  32. Falsetti L, Gambera A, Legrenzi L, Iacobello C, Bugari G. Comparison of finasteride versus flutamide in the treatment of hirsutism. Eur J Endocrinol 1999; 141(4): 361-7.
  33. Falsetti L, Gambera A. Comparison of finasteride and flutamide in the treatment of idiopathic hirsutism. Fertil Steril 1999; 72(1): 41-6.
Journal of Isfahan Medical School
Volume 29, Issue 173 - Serial Number 173
November and December 2012
Pages 3072-3079

Files

History

  • Receive Date: 18 March 2012
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics